Activity Overview
This educational activity is an archive of the live presentation held on February 19, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, radiation oncologists, head & neck surgery/ENT, speech-language pathologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care practitioners involved in the treatment and management of locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the current role of post-CRT surveillance in patients with LA-HNSCC
- Apply risk-stratified strategies to determine appropriate post-CRT management for patients with LA-HNSCC
- Implement coordinated multidisciplinary care plans to mitigate and manage toxicities related to CRT in patients with HNSCC
- Identify potentially eligible patients for ongoing clinical trials evaluating novel post-CRT treatment approaches
Barbara Burtness, MD
Anthony N. Brady Professor of Medicine
Chief Translational Research Officer
Yale Cancer Center
Chief, Head and Neck Cancers/Sarcoma
New Haven, CT
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: ALX Oncology, Answers in CME, AstraZeneca, ClearView Healthcare Partners, Clinical Care Options LLC, Coherus Biosciences, Genentech, Genmab, GSK, Induxion, IO Biotech, Janssen Pharmaceuticals, Med Learning Group, Merck, Merck KGaA, Merus, OncLive, One Carbon, Pfizer, PRIME, Rakuten, Takeda Pharmaceuticals, UpToDate, Yale School of Medicine; Grant/Research Funding (to institution): GSK, IO Biotech, Janssen Pharmaceuticals, Merck; Royalty or Patent Benefits: UpToDate
Quynh-Thu Le, MD, FACR, FASTRO
Katharine Dexter McCormick and
Stanley McCormick Memorial Professor and Chair
Department of Radiation Oncology
Stanford University
Stanford, CA
Disclosures: Executive Role: NRG Oncology Group Chair, Radiation Therapy Oncology Group Foundation Chair
Vlad C. Sandulache, MD, PhD
Associate Professor
Vice Chair, Research
Bobby R. Alford Department of Otolaryngology—Head and Neck Surgery
Baylor College of Medicine
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: FemtoVox Inc, developer of surgical laser system
For more information about this educational activity, the faculty, and disclosures, please click here.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
